stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Total debt
AxoGen, Inc.'s total debt at the end of fiscal 2025 was $67.6M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $17.6M. Over the past ten years it has ranged from $123.0K (fiscal 2018) to $68.7M (fiscal 2024); the current reading is higher than 82% of that period. AxoGen, Inc. ranks 79th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $67.6M | (1.54%) |
| FY2024 | $68.7M | 1.39% |
| FY2023 | $67.7M | 0.47% |
| FY2022 | $67.4M | (0.04%) |
| FY2021 | $67.5M | 25.46% |
| FY2020 | $53.8M | 1,514.05% |
| FY2019 | $3.3M | 2,608.13% |
| FY2018 | $123.0K | (99.50%) |
| FY2017 | $24.6M | 1.38% |
| FY2016 | $24.3M | (1.58%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $17.6M | (2.50%) |
| Jun 2026 | $18.1M | (12.36%) |
| Mar 2026 | $20.6M | (69.48%) |
| Dec 2025 | $67.6M | 3.13% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ITGR Integer Holdings Corporation compare | $1.3B |
| NEOG Neogen Corporation compare | $774.2M |
| IRTC iRhythm Holdings, Inc. compare | $651.9M |
| ESTA Establishment Labs Holdings Inc. compare | $261.7M |
| UFPT UFP Technologies, Inc. compare | $96.0M |
| TMDX TransMedics Group, Inc. compare | $54.8M |
| INSP Inspire Medical Systems, Inc. compare | $25.2M |
| AXGN AxoGen, Inc. | $17.6M |
| ALMR Alamar Biosciences, Inc. compare | $9.9M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement